Targeted Combo Impresses in Resistant Myelofibrosis

(MedPage Today) -- More than a fourth of patients with progressive myelofibrosis achieved durable responses to a BCL pathway inhibitor and a Janus kinase (JAK) inhibitor, a small prospective study showed.
Nine of 34 patients had at least a 35...